ĀÜĄņĀŅĀ×

With a talent for forming multidisciplinary teams to commercialize challenging, valuable new medical products, Dale has successfully commercialized 19 medical devices including combination and PMA products such as the first clinical cell culture system (Stericellā„¢), the first clinical stem cell isolation system (CellProā€™s CePrateā„¢), the first automated food pathogen identification instrument (RiboPrinterā„¢), BioFiberā„¢ products made from a new resorbable polymer, and the first microvascular-based products. He holds 27 issued US patents in 10 disciplines. Dale has helped start-up four companies (CellPro, Intent, MicroVascular Tissues, HemaFlo Therapeutics), three successful joint ventures (Stericell, DePuy-Dupont Orthopedics, Qualicon), and experienced three IPOā€™s (CellPro, DePuy, Tornier). He has also worked at DuPont, Boehringer-Mannheim, J&J, Tornier, and consulted for firms in fields such as cardiovascular devices, stem cells, and tissue replacements. In addition to R&D roles, he led the Tissue Engineering initiative for Ethicon (NBD) and evaluated hundreds of businesses for the Vertical Group. He earned a BS degree in chemical engineering summa cum laude from Brigham Young University and a Ph.D. in chemical engineering from the University of Washington.